Cancers That Are Classified As Indolent Lymphoma
Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to aggressive cancers). These cancers are often very responsive to treatments like chemotherapy, radiation, and immunotherapy. However, the early stages are less responsive, so the "Watch and Wait" method of treatment may be employed.
Radioimmunotherapy is also beginning to become a mainstream treatment with promising results. The Zevalin regimen has been approved for certain types of NHL.
The following are some of the cancers classified as indolent lymphoma:
- Follicular small cleaved cell lymphoma
- Follicular mixed small cleaved and large cell lymphoma
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- T-cell CLL
- Mycosis Fungoides
- MALT lymphoma
- Marginal Zone Nodal lymphoma
- Diffuse small cleaved cell lymphoma
- T-Cell large granular leukemia/lymphoma
- Splenic marginal zone lymphoma
- Lymphoplasmacytic lymphoma
Photo: Pixabay
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
